Amgen heart drug passes interim check, setting up year-end readout

Amgen heart drug passes interim check, setting up year-end readout

Source: 
BioPharma Dive
snippet: 

Results from a large Phase 3 study of omecamtiv mecarbil, which Amgen developed with Cytokinetics, are due in the fourth quarter.